Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?

Area of Science:

• Global Health
• Pharmaceutical Quality Control
• Parasitic Diseases

Background:

• Malaria is a deadly parasitic disease affecting over 3 billion people, predominantly in resource-poor nations.
• Poor-quality antimalarial medicines contribute to substantial preventable deaths, particularly among children under five in sub-Saharan Africa.
• An estimated 122,000 child deaths in sub-Saharan Africa in 2013 were linked to substandard antimalarials.

Purpose of the Study:

• To highlight the critical issue of poor-quality antimalarial medicines.
• To discuss the risks and contributing factors associated with substandard antimalarials.
• To emphasize the need for collective action and technological advancements in combating counterfeit drugs.

Main Methods:

• Review of existing studies on antimalarial drug quality.
• Analysis of factors contributing to the circulation of poor-quality medicines.
• Examination of current strategies and future needs for quality assurance.

Main Results:

• The prevalence of poor-quality antimalarials varies widely, with studies reporting 4-92% of tested products being substandard.
• Substandard antimalarials lead to severe illness, increased healthcare costs, and reduced patient confidence.
• Key factors include weak regulatory systems, insufficient funding, poor regulatory coordination, and ineffective import/export controls.

Conclusions:

• Significant progress has been made in delivering high-quality antimalarials, but challenges remain.
• An urgent, collective international response is required, involving political commitment and increased R&D funding.
• Strengthening and harmonizing drug regulation practices globally, alongside developing innovative field detection technologies, is essential.